ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 148 filers reported holding ARCUS BIOSCIENCES INC in Q4 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,325,600 | -11.6% | 1,968,000 | 0.0% | 5.43% | -2.4% |
| Q2 2023 | $39,970,080 | +0.9% | 1,968,000 | -9.4% | 5.56% | -2.4% |
| Q1 2023 | $39,617,280 | -22.8% | 2,172,000 | -12.5% | 5.70% | -28.7% |
| Q4 2022 | $51,342,236 | -26.4% | 2,482,700 | -7.0% | 7.99% | -33.6% |
| Q3 2022 | $69,803,000 | +3.2% | 2,668,316 | -0.1% | 12.05% | -33.3% |
| Q2 2022 | $67,657,000 | -13.9% | 2,669,974 | +7.2% | 18.06% | +6.3% |
| Q1 2022 | $78,584,000 | -7.3% | 2,489,974 | +18.8% | 16.99% | +3.0% |
| Q4 2021 | $84,794,000 | +150.6% | 2,095,231 | +116.0% | 16.50% | +98.1% |
| Q3 2021 | $33,830,000 | +62.1% | 970,164 | +27.6% | 8.33% | +92.7% |
| Q2 2021 | $20,874,000 | +85.8% | 760,164 | +90.0% | 4.32% | +2.2% |
| Q1 2021 | $11,232,000 | +44.2% | 400,000 | +33.3% | 4.23% | +56.7% |
| Q4 2020 | $7,788,000 | – | 300,000 | – | 2.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |